Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
D000284:Administration, Oral; D000477:Alkylating Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014508:Urea / Q000627:therapeutic use*
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea; D002330:Carmustine; D011241:Prednisone